Antonio Pera Biography and Net Worth

Director of ANI Pharmaceuticals

Mr. Pera has been a member of the Board since August 2020. He served as President of Par Pharmaceuticals Companies, Inc. (“Par”), the fifth-largest generic manufacturer in the United States, which is now part of Endo International, plc, from December 2013 until his retirement in August 2019. Prior to Par, Mr. Pera held leadership positions at AmerisourceBergen, American Pharmaceuticals Partners, Bedford Laboratories, a division of Ben Venue Laboratories, and Baxter Healthcare. His breadth of experience spans sales, marketing, supply chain operations, and licensing, and he has played a pivotal role in the successful growth and commercialization efforts at several successful pharma entities. Mr. Pera holds a B.S. in Business Administration from the University of Illinois at Urbana-Champaign and an M.B.A. from DePaul University.

What is Antonio R. Pera's net worth?: The estimated net worth of Antonio R. Pera is at least $1.87 million as of September 3rd, 2025. Mr. Pera owns 22,660 shares of ANI Pharmaceuticals stock worth more than $1,874,888 as of December 5th. This net worth approximation does not reflect any other assets that Mr. Pera may own. Learn More about Antonio R. Pera's net worth.
How do I contact Antonio R. Pera?: The corporate mailing address for Mr. Pera and other ANI Pharmaceuticals executives is 210 Main Street West, Baudette MN, 56623. ANI Pharmaceuticals can also be reached via phone at (218) 634-3500 and via email at [email protected]. Learn More on Antonio R. Pera's contact information.
Has Antonio R. Pera been buying or selling shares of ANI Pharmaceuticals?: Antonio R. Pera has not been actively trading shares of ANI Pharmaceuticals in the last ninety days. Most recently, Antonio R. Pera sold 7,292 shares of the business's stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $94.94, for a transaction totalling $692,302.48. Following the completion of the sale, the director now directly owns 22,660 shares of the company's stock, valued at $2,151,340.40. Learn More on Antonio R. Pera's trading history.
Who are ANI Pharmaceuticals' active insiders?: ANI Pharmaceuticals' insider roster includes Stephen Carey (CFO), Stephen Carey (Senior Vice President, Finance and Chief Financial Officer), Meredith Cook (Senior Vice President, General Counsel and Corporate Secretary), Krista Davis (Senior Vice President and Chief Human Resources Officer), Chad Gassert (Senior Vice President, Corporate Development and Strategy), Ori Gutwerg (Senior Vice President, Generics), Thomas Haughey (Director), Nikhil Lalwani (Pres), Nikhil Lalwani (President and Chief Executive Officer), Matthew Leonard (Director), James Marken (Senior Vice President, Operations and Product Development), Christopher Mutz (Insider), Antonio Pera (Director), Thomas Rowland (SVP), Muthusamy Shanmugam (Head of R&D and COO of NJ Operations), Muthusamy Shanmugam (Head of R&D and COO), Renee Tannenbaum (Director), Jeanne Thoma (Director), and Patrick Walsh (Director). Learn More on ANI Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ANI Pharmaceuticals?: During the last year, insiders at the specialty pharmaceutical company sold shares 37 times. They sold a total of 455,390 shares worth more than $39,646,631.34. The most recent insider tranaction occured on November, 13th when SVP Chad Gassert sold 94 shares worth more than $8,272.00. Insiders at ANI Pharmaceuticals own 11.1% of the company. Learn More about insider trades at ANI Pharmaceuticals.
Information on this page was last updated on 11/13/2025.

Antonio R. Pera Insider Trading History at ANI Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/3/2025	Sell	7,292	$94.94	$692,302.48	22,660
8/20/2025	Sell	5,421	$89.73	$486,426.33	29,952
8/14/2023	Sell	3,000	$60.37	$181,110.00	33,627

Antonio R. Pera Buying and Selling Activity at ANI Pharmaceuticals

ANI Pharmaceuticals Company Overview

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Today's Range

Now: $82.74

$81.59

$83.47

50 Day Range

MA: $88.73

$78.52

$95.38

2 Week Range

Now: $82.74

$52.50

$99.50

Volume

328,187 shs

Average Volume

453,686 shs

Market Capitalization

$1.86 billion

P/E Ratio

50.76

Dividend Yield

N/A

Beta

0.48